Photo from archive.org
We appreciate the comments from H.Y. Kim and co-workers on our individual patient data meta-analysis on Mycobacterium abscessus pulmonary disease (MAB-PD) [1]. They emphasised the importance of pharmacokinetic (PK)/pharmacodynamic (PD)… Click to show full abstract
We appreciate the comments from H.Y. Kim and co-workers on our individual patient data meta-analysis on Mycobacterium abscessus pulmonary disease (MAB-PD) [1]. They emphasised the importance of pharmacokinetic (PK)/pharmacodynamic (PD) analysis and therapeutic drug monitoring (TDM) in the field of nontuberculous mycobacterial (NTM) disease, especially for MAB-PD. We generally agree with their perspective. Pharmacokinetic, pharmacodynamic and therapeutic drug monitoring data are useful in optimising treatment for Mycobacteriuam abscessus pulmonary disease, but such data are not routinely collected and analysis for clinical practice is difficult http://bit.ly/2pcTIUn
Journal Title: European Respiratory Journal
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!